Security key
140755109
Cara Therapeutics, Inc. - Common Stock, par value $0.001 per share (CARA)
CUSIP: 140755109
Q3 2019 13F Holders as of 30 Sep 2019
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Total 13F shares
- 30,528,396
- Total 13F value
- $558,121,704
- Share change
- +4,504,717
- Put/Call ratio
- 111%
- SEC-reported price per share
- $18.28
- Number of holders
- 140
- Value change
- +$81,405,292
- Number of buys
- 79
- Number of sells
- 48
- Shares outstanding
- 54,790,889
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2019
Institutions
140
Top holders
10
CARA full security history
Ownership snapshot
Full 13F holder table
Tvardi Therapeutics, Inc. SEC filings
Tvardi Therapeutics, Inc. company facts
Broader feeds
Ownership snapshot
Top reported holders of CARA - Cara Therapeutics, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
RHO CAPITAL PARTNERS INC
Disclosed value leader
RHO CAPITAL PARTNERS INC
Comparable rows
15/15
Latest evidence
30 Jun 2019
13F
Lead comparable stake: 6%
Showing 1-6 of 15 holder rows.
Quick read
RHO CAPITAL PARTNERS INC leads the comparable SEC ownership view at 6%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens RHO CAPITAL PARTNERS INC's linked filing trail.
Comparable ownership
Top 5
RHO CAPITAL PARTNERS INC
6%
BlackRock Finance, Inc.
5.2%
PRICE T ROWE ASSOCIATES INC /MD/
5.1%
FIRST MANHATTAN CO. LLC.
3.5%
STATE STREET CORP
3.3%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| RHO CAPITAL PARTNERS INC |
13F
Company
|
6%
|
$70,263,000
3,268,057 shares
|
— | 30 Jun 2019 |
| BlackRock Finance, Inc. |
13F
Company
|
5.2%
|
$61,587,000
2,864,551 shares
|
— | 30 Jun 2019 |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
Company
|
5.1%
|
$60,207,000
2,800,339 shares
|
— | 30 Jun 2019 |
| FIRST MANHATTAN CO. LLC. |
13F
Company
|
3.5%
|
$41,671,000
1,938,188 shares
|
— | 30 Jun 2019 |
| STATE STREET CORP |
13F
Company
|
3.3%
|
$39,417,000
1,833,354 shares
|
— | 30 Jun 2019 |
| VANGUARD GROUP INC |
13F
Company
|
3.2%
|
$38,258,000
1,779,452 shares
|
— | 30 Jun 2019 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2019
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
140
Shares
30,528,396
Rows available
140
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2019 vs Q2 2019 Across Filers
Q2 2019 holders
122
Q3 2019 holders
140
Holder diff
18
| Investor | Q2 2019 Shares | Q3 2019 Shares | Share Diff | Share Chg % | Q2 2019 value | Q3 2019 value | Value change | Value Chg % |
|---|